Biocon API facility in Telangana completes USFDA inspection
17 December 2018 | News
The inspection concluded without any observations and no Form 483 was issued.
Biocon Ltd, Asia’s premier biopharmaceuticals company, has recently announced that the USFDA conducted a Good Manufacturing Practice (GMP) inspection of the APIs manufacturing facility at Telangana from Dec 12- Dec 14, 2018. The inspection concluded without any observations and no Form 483 was issued.
According to the company, the successful inspection of this site reflects their strong commitment to quality and Current Good Manufacturing Practice (cGMP) compliance.
